Dana Brown and Timothy Norris Irish offer extensive experience in
technology, women’s breast health and unique global perspectives

N.H., January 11, 2022 — iCAD, Inc. (NASDAQ: ICAD), a global medical
technology leader providing innovative cancer detection and therapy solutions,
announced today it has appointed Dana Brown and Timothy Norris Irish as new
independent members of the Board of Directors, effective January 10, 2022. As
previously announced, the Company also added Stacey Stevens, iCAD’s President
and incoming CEO to the Board of Directors, bringing the total number of Board
members to eight.

A 30-year technology industry veteran, Ms. Brown is
currently the Senior Vice President, Chief Strategy and Operations Officer at
Susan G. Komen® the world’s leading nonprofit breast cancer organization
supporting millions of people in the U.S. and in countries worldwide by
advocating for patients, driving research breakthroughs, improving access to
high-quality care, offering direct patient support and empowering people with
trustworthy information. Prior to that role, she served as Senior Vice
President and Chief Digital Officer at United Way Worldwide. Ms. Brown was also
a founding team member of multiple successful ventures including co-founder and
CMO for MetaSolv Software, CEO of Ipsum Networks and spent the early years of
her career at Texas Instruments and Arthur Andersen.

“iCAD’s commitment to delivering innovative AI-based
breast cancer detection and therapy capabilities that improve the patient
experience and clinical decision support for providers is to be commended and I
look forward to working with the team, who is equally as passionate about
improving women’s health and optimizing outcomes for patients,” said Ms. Brown.
“It is an honor to join iCAD’s Board of Directors, and to be a part of this
values-led company that is laser focused on innovation and growth.”

An experienced leader in the life sciences and healthcare
sectors, Professor Timothy Norris Irish is currently a Professor at the Business
School at King’s College London (KCL). He also is currently a Trustee of Picker
Institute Europe and Committee member of the Alzheimer’s Society, in addition
to several other remunerated Board roles at KHP Medtech Innovations, Team
Consulting Ltd. ImaginAb Inc, eZono AG, Feedback Plc and Deltex Medical Group
Plc. Prof. Irish also recently served as Vice Chair at the National Institute
for Health and Care Excellence (NICE), where he previously held the roles of
Acting Chair and Independent Director.

“As a global company with a well-established portfolio of
products currently available across the U.S. and more than 15 countries outside
the U.S., iCAD’s technology is already making a positive impact on the lives of
many patients worldwide,” said Prof. Irish. “I am honored to join iCAD’s Board
of Directors and look forward to working with the team to help drive the
adoption of the Company’s leading-edge technologies that are addressing some of
the most urgent and complex challenges in healthcare today.”

are pleased to welcome Ms. Brown and Prof. Irish to the Board as they each
offer tremendous insight and decades of relevant experience in corporate
leadership, brand stewardship, and health technologies, along with a proven
track record of leading innovation and strategic change,” said Ms. Stevens.
“With Ms. Brown’s experience in technology and women’s breast health, and Prof.
Irish’s global expertise, these appointments will offer our Company unique and
fresh perspectives in areas that stand to benefit both the Detection and
Therapy sides of our business, while also underscoring the Company’s commitment
to increasing shareholder value.”

About iCAD, Inc.

Headquartered in Nashua, NH, iCAD® is
a global medical technology leader providing innovative cancer detection and
therapy solutions. For more information, visit www.icadmed.com and www.xoftinc.com.


Forward-Looking Statements

Certain statements contained in this
News Release constitute “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, including statements about
the expected benefits of the Company’s new directors. Such forward-looking
statements involve a number of known and unknown risks, uncertainties and other
factors which may cause the actual results, performance or achievements of the
Company to be materially different from any prior results, performance or
achievements expressed or implied by such forward-looking statements. Such
factors include, but are not limited, to the Company’s ability to achieve
positive results from this or any future studies, business and strategic
objectives, the ability of IORT to provide flexibility, mobility or other
advantages, to be more beneficial for patients than traditional therapy or to
be accepted by patients or clinicians, the impact of supply and manufacturing
constraints or difficulties, product market acceptance, possible technological
obsolescence of products, increased competition, litigation and/or government
regulation, changes in Medicare or other reimbursement policies, risks relating
to our existing and future debt obligations, competitive factors, the effects
of a decline in the economy or markets served by the Company; and other risks
detailed in the Company’s filings with the Securities and Exchange Commission.
The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,”
“continue,” “anticipate,” “likely,” “seek,” and similar expressions identify
forward-looking statements. Readers are cautioned not to place undue reliance
on those forward-looking statements, which speak only as of the date the
statement was made. The Company is under no obligation to provide any updates
to any information contained in this release. For additional disclosure
regarding these and other risks faced by iCAD, please see the disclosure
contained in our public filings with the Securities and Exchange Commission,
available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.


Media Inquiries:

Jessica Burns, iCAD  




Investor Relations:

Brian Ritchie, LifeSci Advisors